ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

28 أبريل 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 أبريل 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

31 مارس 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

25 مارس 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 مارس 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

25 فبراير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

18 فبراير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 فبراير 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 يناير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

13 يناير 2025 07:05:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

13 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 يناير 2025 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 يناير 2025 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

25 نوفمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12 نوفمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04 نوفمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 15:30:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

23 أكتوبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 أكتوبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 أكتوبر 2024 15:30:00 بحسب Nasdaq GlobeNewswire